Adia Nutrition Launches Clinical Study to Evaluate AdiaVita for Autism Spectrum Disorder
Adia Nutrition has announced a major partnership with a leading clinic in Atlanta to initiate a groundbreaking clinical study focused on Autism Spectrum Disorder (ASD). The research aims to evaluate the efficacy of AdiaVita, a specialized product derived from umbilical cord blood, in improving outcomes for individuals with autism.
What is AdiaVita?
AdiaVita is a product derived from umbilical cord blood. It is characterized by being rich in exosomes and stem cells, which are the primary components being tested in this clinical application. By leveraging these biological elements, the study seeks to determine if this approach can provide therapeutic benefits for those on the autism spectrum.
Details of the Atlanta Clinical Study
The research, registered as NCT07304440, is a 24-month study designed to explore a combination therapy approach. Rather than using AdiaVita in isolation, the study is testing whether adding AdiaVita to glutathione therapy helps improve outcomes for participants.
The partnership with the Atlanta-based clinic allows for a controlled environment to monitor the effects of this stem cell and exosome-rich product over a two-year period.
Key Takeaways
- Partnership: Adia Nutrition is collaborating with a leading Atlanta clinic to conduct the research.
- The Product: AdiaVita is derived from umbilical cord blood and contains stem cells, and exosomes.
- Study Duration: The clinical trial is scheduled to last 24 months.
- Combined Approach: The study specifically tests the addition of AdiaVita to existing glutathione therapy.
- Objective: To determine if this combination improves outcomes for individuals with Autism Spectrum Disorder.
Looking Ahead
As the 24-month study progresses, the medical community will be looking for evidence-based results regarding the integration of umbilical cord blood-derived products into autism treatment protocols. This research represents a significant step in exploring how stem cells and exosomes might be utilized alongside traditional therapies to support those with ASD.